BJE6-106

Overview

BJE6-106 (B106) is a potent, selective 3 rd generation PKCδ inhibitor with an IC 50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC 50 =50 μM). BJE6-106 (B106) induces caspase-dependent apoptosis . BJE6-106 (B106) possesses tumor-specific effect.

Application

Products | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PKC | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-117800
• CAS No.: 1564249-38-2
• Molecular Formula: C26H23NO2
• Molecular Weight: 381.47
• Purity: 99.85%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (6.55 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source